Bb Biotech Ag Stock Fundamentals
| BBZA Stock | 37.55 0.45 1.18% |
BB Biotech AG fundamentals help investors to digest information that contributes to BB Biotech's financial success or failures. It also enables traders to predict the movement of BBZA Stock. The fundamental analysis module provides a way to measure BB Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BB Biotech stock.
BBZA |
BB Biotech AG Company Shares Outstanding Analysis
BB Biotech's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BB Biotech Shares Outstanding | 54.85 M |
Most of BB Biotech's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, BB Biotech AG has 54.85 M of shares currently outstending. This is 69.62% lower than that of the Healthcare sector and 48.67% lower than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 90.41% higher than that of the company.
BB Biotech AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BB Biotech's current stock value. Our valuation model uses many indicators to compare BB Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BB Biotech competition to find correlations between indicators driving BB Biotech's intrinsic value. More Info.BB Biotech AG is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BB Biotech's earnings, one of the primary drivers of an investment's value.BBZA Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.BB Biotech is currently under evaluation in shares outstanding category among its peers.
BBZA Fundamentals
| Return On Equity | -0.12 | |||
| Return On Asset | -0.008 | |||
| Current Valuation | 218.38 M | |||
| Shares Outstanding | 54.85 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 7.82 % | |||
| Price To Book | 1.26 X | |||
| Price To Sales | 782,390 X | |||
| Revenue | (351.23 M) | |||
| Gross Profit | 4 K | |||
| EBITDA | (356.02 M) | |||
| Net Income | (357.81 M) | |||
| Book Value Per Share | 48.98 X | |||
| Cash Flow From Operations | (94.79 M) | |||
| Earnings Per Share | (6.37) X | |||
| Target Price | 84.9 | |||
| Number Of Employees | 10 | |||
| Beta | 0.87 | |||
| Market Capitalization | 3.16 B | |||
| Total Asset | 3.05 B | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 3.05 B | |||
| Last Dividend Paid | 2.85 |
About BB Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BBZA Stock
BB Biotech financial ratios help investors to determine whether BBZA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBZA with respect to the benefits of owning BB Biotech security.